Table 1.
Summary of cell culture treatments.
| Pharmacological Inhibitors | |||||
|---|---|---|---|---|---|
| Inhibitor | Target | Catalogue # | Source | Working Concentration(s) |
Vehicle |
| SB431542 | TGFβ Type 1 Receptor | S1067 | Selleck Chemicals (Houston, TX, USA) |
10 μM | 0.1% DMSO |
| LY-294,002 | PI3K | S1105 | Selleck Chemicals (Houston, TX, USA) |
20 μM | 0.1% DMSO |
| MK2206 | AKT | S1078 | Selleck Chemicals (Houston, TX, USA) |
300 nM | 0.1% DMSO |
| U0127 | MEK | V1121 | Promega (Madison, WI, USA) |
10 μM | 0.1% DMSO |
| Rapamycin | mTORC1/2 | S1039 | Selleck Chemicals (Houston, TX, USA) |
10 nM | 0.1% DMSO |
| OSI-906 | IGF-1 Receptor | S1091 | Selleck Chemicals (Houston, TX, USA) |
1 nM, 1 μM, 10 μM |
0.1% DMSO |
| Growth Factor Treatments | |||||
| Growth Factor | Catalogue # | Source | Working Concentration(s) |
Vehicle | |
| TGFβ | 240-B | R&D Systems (Minneapolis, MN, USA) |
10 ng/ml | 4 mM HCl, 0.1% BSA |
|
| IGF-1 (mouse) | 9897 | Cell Signaling (Danvers, MA, USA) |
0.2 ng/ml | 20mM citrate, pH 3.0 |
|
| IGF-1 (human) | ab9573 | Abcam (Cambridge, MA, USA) |
2 ng/ml | dH2O | |